Real-world effectiveness of first-line chemoimmunotherapy versus chemotherapy in older adults with extensive-stage small cell lung cancer: an inverse probability treatment weighted analysis.
Oct 2026· Future Oncology· pp.
1-12
· 0 citations· 29 references
Medicine
TL;DR
Comparison evidence of improved survival in association with ICI-chemo compared with chemo in older adults with ES-SCLC is provided, providing comparative evidence of improved survival in association with ICI-chemo.
Abstract
Aims
First-line chemoimmunotherapy (ICI-chemo) has become the standard of care for extensive-stage small cell lung cancer (ES-SCLC). However, older adults are underrepresented in pivotal trials due to strict inclusion criteria that limit participation to highly selected, fit patients. Given the limited real-world comparative data, this study aimed to determine whether older adults with ES-SCLC derive greater benefit from ICI-chemo compared with chemotherapy (chemo) alone.
PATIENTS AND
Methods
We conducted a single-center retrospective cohort study including ES-SCLC patients aged 65 years or older who started first-line ICI-chemo or chemo between January 2020 and July 2024. Inverse probability of treatment weighting (IPTW) was used to adjust for baseline confounding. The main outcome was overall survival (OS) in the IPTW population.
Results
In the IPTW population, median OS was significantly longer in the ICI-chemo group (14.95 months; 95% CI, 12.94-19.91) compared with chemo (10.28 months; 95% CI, 8.11-13.17; HR, 0.66; 95% CI, 0.48-0.91; p = 0.011). Multivariable analysis confirmed that ICI-chemo exposure was independently associated with improved OS (HR, 0.608; 95% CI, 0.440-0.841; p = 0.003).
Conclusions
Our findings provide comparative evidence of improved survival in association with ICI-chemo compared with chemo in older adults with ES-SCLC.
Abstract Background Platinum-etoposide (PE) chemotherapy combined with a programmed cell death ligand 1 (PD-L1) inhibitor is the current first-line (1L) standard of care for extensive-stage small cell lung cancer (ES-SCLC). Real-world evidence describing outcomes across induction and maintenance phases remains limited....
Yi-Shao Liu, P. Desai, H. Khurshid et al.· The Oncologist· 0 citations
Background and Objectives: This study aimed to compare the real-world outcomes of first-line pembrolizumab monotherapy (Mono-IO) versus pembrolizumab plus platinum-based chemotherapy (IO + ChT) in patients with metastatic non-small cell lung cancer (mNSCLC) and a PD-L1 tumor proportion score (TPS) ≥ 50%. Materials and...
Ozde Melisa Celayir, B. Köylü, Harun Muğlu et al.· Medicina· 0 citations
Background Extensive-stage small-cell lung cancer (ES-SCLC) remains an aggressive malignancy with poor survival despite platinum-etoposide chemotherapy. Although serplulimab plus chemotherapy has demonstrated a survival benefit in randomized trials, comparative real-world evidence remains limited. We therefore evaluate...
Y. Jing, Miao Li, Song-Xiang Li et al.· Journal of Cancer· 0 citations
Background Extensive-stage small cell lung cancer (ES-SCLC) is highly aggressive with dismal prognosis, and platinum monochemotherapy offers modest long-term survival. Multiple first-line regimens integrating immunotherapy, anti-angiogenic agents and chemotherapy have been approved, yet direct head-to-head comparisons...
Hong-Jing Yu, Jun-Chen Liu, Dong-Sheng Zhang et al.· Frontiers in Pharmacology· 0 citations
Real-world evidence is provided supporting the use of ICI-based therapy in SCLC, particularly in advanced-stage disease, but should be interpreted cautiously given the retrospective design and subgroup sample sizes.
Peng-Hu Gao, Hong-Bing Zhang, Ming-Hui Liu et al.· Frontiers in Oncology· 0 citations